• Publications
  • Influence
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B
TLDR
The enforced expression of miR-29s in lung cancer cell lines restores normal patterns of DNA methylation, induces reexpression of methylation-silenced tumor suppressor genes, and inhibits tumorigenicity in vitro and in vivo. Expand
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.
TLDR
Novel functional links between miRNAs and aberrant DNA hypermethylation in acute myeloid leukemia and suggest a potentially therapeutic use of synthetic miR-29b oligonucleotides as effective hypomethylating compounds are provided. Expand
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.
TLDR
It is concluded that depsipeptide effectively inhibits HDAC in vivo in patients with CLL and AML, but its use in the current schedule of administration is limited by progressive constitutional symptoms. Expand
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
TLDR
Low-dose decitabine was safe and showed encouraging clinical and biologic activity in AML, but the addition of VA led to encephalopathy at relatively low doses. Expand
Curcumin is a potent DNA hypomethylation agent.
TLDR
Curcumin inhibits the activity of M. SssI with an IC(50) of 30 nM, but no inhibitory activity of hexahydrocurcumin up to 100 microM, and can induce global DNA hypomethylation in a leukemia cell line. Expand
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
TLDR
The maximum tolerated dose (MTD) of depsipeptide given on a day-1 and -5 schedule every 21 days was defined and biological assays showed that the serum levels achieved could cause the characteristic cell cycle effects of this agent when serum was added to PC3 cells in culture, as well as increased histone acetylation in patient-derived peripheral blood mononuclear cells. Expand
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.
TLDR
These results provide evidence that the mechanisms of Sp1/NFkappaB/HDAC/miR-29b-dependent KIT overexpression contribute to leukemia growth and can be successfully targeted by pharmacological disruption of the Sp1 /NFkappB/ HDAC complex or synthetic miR- 29b treatment in KIT-driven AML. Expand
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
TLDR
This schedule of decitabine was highly active and well tolerated in this poor-risk cohort of older AML patients and levels of miR-29b should be validated as a predictive factor for stratification of olderAML patients to decitABine treatment. Expand
Modulation of DNA Methylation by a Sesquiterpene Lactone Parthenolide
TLDR
Parthenolide is established as an effective DNA methylation inhibitor, representing a novel prototype for DNMT1 inhibitor discovery and development from natural structural-diversified sesquiterpene lactones. Expand
Carotenoids/vitamin C and smoking‐related bladder cancer
TLDR
The protective effect of carotenoids on bladder cancer seemed to be influenced by NAT1 genotype, NAT2 phenotype and CYP1A2 phenotype; the association was mainly confined to subjects possessing the putative NAT1‐rapid, NAT1-rapid and CYF2‐rapids genotype/phenotype. Expand
...
1
2
3
4
5
...